STOCK TITAN

Nanostring Technologies Inc - NSTG STOCK NEWS

Welcome to our dedicated news page for Nanostring Technologies (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on Nanostring Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanostring Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanostring Technologies's position in the market.

Rhea-AI Summary
NanoString Technologies to webcast presentations at upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
conferences
-
Rhea-AI Summary
NanoString Technologies appoints Todd Garland as Chief Commercial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
management
-
Rhea-AI Summary
NanoString Technologies announces breakthrough study on pig-to-human organ transplants featured in The Lancet medical journal
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.71%
Tags
-
Rhea-AI Summary
NanoString Technologies, Inc. comments on the court order in its patent litigation with 10x Genomics and Harvard College. The court granted NanoString's motion to add counterclaims for antitrust and unfair competition violations. NanoString claims that Harvard made a non-exclusive licensing commitment to secure grant funding from the NIH, but then exclusively licensed the patents to Readcoor, acquired by 10x. The court ruling supports NanoString's strategy in Germany and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
Rhea-AI Summary
NanoString Technologies reports strong Q2 revenue of over $44 million, exceeding estimates and upper end of guidance range. Spatial biology revenue at approximately $23 million, nCounter revenue at approximately $21 million. CosMx instrument orders fulfilled or retained at 97%, with new orders exceeding Q1 pace. Full year revenue guidance reiterated at $175-185 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.92%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.13%
Tags
none
Nanostring Technologies Inc

Nasdaq:NSTG

NSTG Rankings

NSTG Stock Data

5.07M
39.41M
3.17%
106.45%
12.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Seattle

About NSTG

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali